Personalized Medicine in Brain Tumors

Quintino Giorgio D’Alessandris,Martina Offi,Liverana Lauretti,Roberto Pallini,Quintino Giorgio D'Alessandris

DOI: https://doi.org/10.3390/jpm14040413

IF: 3.5083

2024-04-13

Journal of Personalized Medicine

Abstract:Personalizing clinical, diagnostic and therapeutic approaches in neuro-oncology is a huge challenge [...]

medicine, general & internal,health care sciences & services

What problem does this paper attempt to address?

Personalization of medical treatments in oncology: time for rethinking the disease concept to improve individual outcomes

Mariano Bizzarri,Valeria Fedeli,Noemi Monti,Alessandra Cucina,Maroua Jalouli,Saleh H Alwasel,Abdel Halim Harrath

DOI: https://doi.org/10.1007/s13167-021-00254-1

2021-10-07

Abstract:The agenda of pharmacology discovery in the field of personalized oncology was dictated by the search of molecular targets assumed to deterministically drive tumor development. In this perspective, genes play a fundamental "causal" role while cells simply act as causal proxies, i.e., an intermediate between the molecular input and the organismal output. However, the ceaseless genomic change occurring across time within the same primary and metastatic tumor has broken the hope of a personalized treatment based only upon genomic fingerprint. Indeed, current models are unable in capturing the unfathomable complexity behind the outbreak of a disease, as they discard the contribution of non-genetic factors, environment constraints, and the interplay among different tiers of organization. Herein, we posit that a comprehensive personalized model should view at the disease as a "historical" process, in which different spatially and timely distributed factors interact with each other across multiple levels of organization, which collectively interact with a dynamic gene-expression pattern. Given that a disease is a dynamic, non-linear process - and not a static-stable condition - treatments should be tailored according to the "timing-frame" of each condition. This approach can help in detecting those critical transitions through which the system can access different attractors leading ultimately to diverse outcomes - from a pre-disease state to an overt illness or, alternatively, to recovery. Identification of such tipping points can substantiate the predictive and the preventive ambition of the Predictive, Preventive and Personalized Medicine (PPPM/3PM). However, an unusual effort is required to conjugate multi-omics approaches, data collection, and network analysis reconstruction (eventually involving innovative Artificial Intelligent tools) to recognize the critical phases and the relevant targets, which could help in patient stratification and therapy personalization.
Personalized Medicine for Patients with Liver, Biliary Tract, and Pancreatic Cancer

Monica Valente,Alessia Covre,Anna Maria Di Giacomo,Michele Maio

DOI: https://doi.org/10.1007/978-3-030-37482-2_50-1

2021-01-01

Abstract:Cancers of the liver, biliary tract, and pancreas are among the gravest and most challenging issues for medical oncologists, being substantially chemo-resistant malignancies. In spite of the increasing incidence of hepato-biliary and pancreatic cancers, the initial diagnosis is often delayed due to the lack of specificity of the accompanying clinical symptoms. Apart from surgery when feasible, and unlike other tumor types, medical therapy has yet to provide significant improvement in the management of the advanced disease; thus, a limited number of new therapeutic agents have been approved in recent years. Nevertheless, in this still highly unsatisfactory scenario, the advances in genome science and in molecular and immuno-biologic knowledge of cancer are translating in a therapeutic and diagnostic improvement. Indeed, a personalized medicine approach may increasingly help to identify the more promising and effective individualized treatments for patients with hepato-biliary and pancreatic malignancies.
Personalized medicine: Clinical oncology on molecular view of treatment

Rafick Costa Dos Santos Da Silva,Nathalia de Andrade Simon,André Alves Dos Santos,Gabriel De Melo Olegário,Jayne Ferreira Da Silva,Naide Oliveira Sousa,Manuel Alvarez Troncoso Corbacho,Fabrício Freire de Melo

DOI: https://doi.org/10.5306/wjco.v15.i8.992

2024-08-24

Abstract:Cancer, the second leading global cause of death, impacts both physically and emotionally. Conventional treatments such as surgeries, chemotherapy, and radiotherapy have adverse effects, driving the need for more precise approaches. Precision medicine enables more targeted treatments. Genetic mapping, alongside other molecular biology approaches, identifies specific genes, contributing to accurate prognoses. The review addresses, in clinical use, a molecular perspective on treatment. Biomarkers like alpha-fetoprotein, beta-human chorionic gonadotropin, 5-hydroxyindoleacetic acid, programmed death-1, and cytotoxic T lymphocyte-associated protein 4 are explored, providing valuable information. Bioinformatics, with an emphasis on artificial intelligence, revolutionizes the analysis of biological data, offering more accurate diagnoses. Techniques like liquid biopsy are emphasized for early detection. Precision medicine guides therapeutic strategies based on the molecular characteristics of the tumor, as evidenced in the molecular subtypes of breast cancer. Classifications allow personalized treatments, highlighting the role of trastuzumab and endocrine therapies. Despite the benefits, challenges persist, including high costs, tumor heterogeneity, and ethical issues. Overcoming obstacles requires collaboration, ensuring that advances in molecular biology translate into accessible benefits for all.
Personalized Medicine: Recent Progress in Cancer Therapy

Valentina Gambardella,Noelia Tarazona,Juan Miguel Cejalvo,Pasquale Lombardi,Marisol Huerta,Susana Roselló,Tania Fleitas,Desamparados Roda,Andres Cervantes

DOI: https://doi.org/10.3390/cancers12041009

2020-04-19

Cancers

Abstract:Translational research has revolutionized how we develop new treatments for cancer patients. The change from an organ-centric concept guiding treatment choice towards deep molecular analysis, driving a personalized approach, is one of the most important advances of modern oncology. Several tools such as next generation sequencing and RNA sequencing have greatly improved the capacity to detect predictive and prognostic molecular alterations. Detection of gene mutations, amplifications, and fusions has therefore altered the history of several diseases in both a localized and metastatic setting. This shift in perspective, in which attention is focused on the specific molecular alterations of the tumor, has opened the door to personalized treatment. This situation is reflected in the increasing number of basket trials selecting specific molecular targets. Nonetheless, some weaknesses need to be addressed. The complexity of cancer cells enriched with concomitant molecular alterations complicates identification of the driver. Moreover, tumor heterogeneity could be responsible for the lack of benefit when targeted agents are used. In light of this, there is growing interest in the role of multidisciplinary committees or molecular tumor boards to try to enhance selection. The aim of this review is to critically analyze the evolution of cancer treatment towards a precision approach, underlining some recent successes and unexpected failures.

oncology
Foundations for a Personalized Psycho-Oncology: The State of the Art

Giampaolo Perna,Eleonora Pinto,Alessandro Spiti,Tatiana Torti,Michele Cucchi,Daniela Caldirola

DOI: https://doi.org/10.3390/jpm14090892

2024-08-23

Abstract:Personalized psycho-oncology represents a major challenge for the holistic care of cancer patients. It focuses on individualized psychotherapeutic and psychiatric interventions to address specific psychological needs. This narrative review summarizes the current literature on personalized psycho-oncology and highlights the prevalence and impact of psychiatric/psychological disorders in cancer patients. Personalized approaches, including tailored interventions and interdisciplinary collaboration, have been shown to be effective in improving mental health and overall quality of life. The integration of inflammatory biomarkers into treatment plans is a promising but challenging way to alleviate mental health problems. In addition, there is a need for specific diagnostic tools and treatment guidelines that take into account the specific psychological impact of different types of cancer. Future research should aim to refine these personalized strategies, improve diagnostic accuracy, and evaluate the cost-effectiveness of these interventions to improve both the psychological well-being and treatment outcomes of cancer patients.
Personalized Clinical Phenotyping through Systems Medicine and Artificial Intelligence

Alfredo Cesario,Marika D’Oria,Francesco Bove,Giuseppe Privitera,Ivo Boškoski,Daniela Pedicino,Luca Boldrini,Carmen Erra,Claudia Loreti,Giovanna Liuzzo,Filippo Crea,Alessandro Armuzzi,Antonio Gasbarrini,Paolo Calabresi,Luca Padua,Guido Costamagna,Massimo Antonelli,Vincenzo Valentini,Charles Auffray,Giovanni Scambia

DOI: https://doi.org/10.3390/jpm11040265

IF: 3.5083

2021-04-02

Journal of Personalized Medicine

Abstract:Personalized Medicine (PM) has shifted the traditional top-down approach to medicine based on the identification of single etiological factors to explain diseases, which was not suitable for explaining complex conditions. The concept of PM assumes several interpretations in the literature, with particular regards to Genetic and Genomic Medicine. Despite the fact that some disease-modifying genes affect disease expression and progression, many complex conditions cannot be understood through only this lens, especially when other lifestyle factors can play a crucial role (such as the environment, emotions, nutrition, etc.). Personalizing clinical phenotyping becomes a challenge when different pathophysiological mechanisms underlie the same manifestation. Brain disorders, cardiovascular and gastroenterological diseases can be paradigmatic examples. Experiences on the field of Fondazione Policlinico Gemelli in Rome (a research hospital recognized by the Italian Ministry of Health as national leader in “Personalized Medicine” and “Innovative Biomedical Technologies”) could help understanding which techniques and tools are the most performing to develop potential clinical phenotypes personalization. The connection between practical experiences and scientific literature highlights how this potential can be reached towards Systems Medicine using Artificial Intelligence tools.

medicine, general & internal,health care sciences & services
Personalized Cancer Therapy Using a Patient-Derived Tumor Tissue Xenograft Model: a Translational Field Worthy of Exploring Further?

Ketao Jin,Kuifeng He,Guangliang Li,Lisong Teng

DOI: https://doi.org/10.2217/pme.10.48

2010-01-01

Personalized Medicine

Abstract:It has long been observed that interpatient variability in response to anticancer drugs is associated with different outcomes. Oncologists continually hold the desire of matching the right therapeutic regimen with the right cancer patient, which is termed 'personalized cancer therapy'. Rapid advances in genetics, genomics and related technologies are promising a new era of personalized cancer therapy based on individual molecular biomarkers. However, these molecular predictors of tumor response are far from perfect. Because of the inherent limitations in the current approaches for anticancer drugs response prediction, the need for new techniques to predict tumor response to therapy is urgent. Using a patient-derived human tumor tissue (PDTT) xenograft model to predict tumor response to therapy might be an ideal candidate method to choose. This article provides an overview of the achievements and limitations of genetic, genomic and proteomic molecular markers for personalized cancer therapy, and further discusses the potentials of using a PDTT xenograft model as a candidate strategy for personalized cancer therapy.
Advances in Personalized Oncology

Hiba Mechahougui,James Gutmans,Gina Colarusso,Roumaïssa Gouasmi,Alex Friedlaender

DOI: https://doi.org/10.3390/cancers16162862

2024-08-18

Cancers

Abstract:Advances in next-generation sequencing (NGS) have catalyzed a paradigm shift in cancer treatment, steering the focus from conventional, organ-specific protocols to precision medicine. Emerging targeted therapies offer a cutting-edge approach to cancer treatment, while companion diagnostics play an essential role in aligning therapeutic choices with specific molecular changes identified through NGS. Despite these advances, interpreting the clinical implications of a rapidly expanding catalog of genetic mutations remains a challenge. The selection of therapies in the presence of multiple mutations requires careful clinical judgment, supported by quality-centric genomic testing that emphasizes actionable mutations. Molecular tumor boards can play an increasing role in assimilating genomic data into clinical trials, thereby refining personalized treatment approaches and improving patient outcomes.

oncology
Nanomedicine for cancer patient-centered care

Carlo Sorrentino,Stefania Livia Ciummo,Cristiano Fieni,Emma Di Carlo

DOI: https://doi.org/10.1002/mco2.767

2024-10-20

Abstract:Cancer is a leading cause of morbidity and mortality worldwide, and an increase in incidence is estimated in the next future, due to population aging, which requires the development of highly tolerable and low-toxicity cancer treatment strategies. The use of nanotechnology to tailor treatments according to the genetic and immunophenotypic characteristics of a patient's tumor, and to allow its targeted release, can meet this need, improving the efficacy of treatment and minimizing side effects. Nanomedicine-based approach for the diagnosis and treatment of cancer is a rapidly evolving field. Several nanoformulations are currently in clinical trials, and some have been approved and marketed. However, their large-scale production and use are still hindered by an in-depth debate involving ethics, intellectual property, safety and health concerns, technical issues, and costs. Here, we survey the key approaches, with specific reference to organ-on chip technology, and cutting-edge tools, such as CRISPR/Cas9 genome editing, through which nanosystems can meet the needs for personalized diagnostics and therapy in cancer patients. An update is provided on the nanopharmaceuticals approved and marketed for cancer therapy and those currently undergoing clinical trials. Finally, we discuss the emerging avenues in the field and the challenges to be overcome for the transfer of nano-based precision oncology into clinical daily life.
Personalised Medicine: Taking a New Look at the Patient

Marco Scutari

DOI: https://doi.org/10.48550/arXiv.1401.2649

2014-01-13

Abstract:Personalised medicine strives to identify the right treatment for the right patient at the right time, integrating different types of biological and environmental information. Such information come from a variety of sources: omics data (genomic, proteomic, metabolomic, etc.), live molecular diagnostics, and other established diagnostics routinely used by medical doctors. Integrating these different kinds of data, which are all high-dimensional, presents significant challenges in knowledge representation and subsequent reasoning. The ultimate goal of such a modelling effort is to elucidate the flow of information that links genes, protein signalling and other physiological responses to external stimuli such as environmental conditions or the progress of a disease.

Applications
Hacking Pancreatic Cancer: Present and Future of Personalized Medicine

Alessandro Di Federico,Valentina Tateo,Claudia Parisi,Francesca Formica,Riccardo Carloni,Giorgio Frega,Alessandro Rizzo,Dalia Ricci,Mariacristina Di Marco,Andrea Palloni,Giovanni Brandi

DOI: https://doi.org/10.3390/ph14070677

IF: 4.6

2021-07-15

Pharmaceuticals

Abstract:Pancreatic cancer (PC) is a recalcitrant disease characterized by high incidence and poor prognosis. The extremely complex genomic landscape of PC has a deep influence on cultivating a tumor microenvironment, resulting in the promotion of tumor growth, drug resistance, and immune escape mechanisms. Despite outstanding progress in personalized medicine achieved for many types of cancer, chemotherapy still represents the mainstay of treatment for PC. Olaparib was the first agent to demonstrate a significant benefit in a biomarker-selected population, opening the doors for a personalized approach. Despite the failure of a large number of studies testing targeted agents or immunotherapy to demonstrate benefits over standard chemotherapy regimens, some interesting agents, alone or in combination with other drugs, have achieved promising results. A wide spectrum of therapeutic strategies, including immune-checkpoint inhibitors tyrosine kinase inhibitors and agents targeting metabolic pathways or the tumor microenvironment, is currently under investigation. In this review, we aim to provide a comprehensive overview of the current landscape and future directions of personalized medicine for patients affected by PC.

pharmacology & pharmacy,chemistry, medicinal
A Systems Approach to Brain Tumor Treatment

James H. Park,Adrian Lopez Garcia de Lomana,Diego M. Marzese,Tiffany Juarez,Abdullah Feroze,Parvinder Hothi,Charles Cobbs,Anoop P. Patel,Santosh Kesari,Sui Huang,Nitin S. Baliga

DOI: https://doi.org/10.3390/cancers13133152

2021-06-24

Cancers

Abstract:Brain tumors are among the most lethal tumors. Glioblastoma, the most frequent primary brain tumor in adults, has a median survival time of approximately 15 months after diagnosis or a five-year survival rate of 10%; the recurrence rate is nearly 90%. Unfortunately, this prognosis has not improved for several decades. The lack of progress in the treatment of brain tumors has been attributed to their high rate of primary therapy resistance. Challenges such as pronounced inter-patient variability, intratumoral heterogeneity, and drug delivery across the blood–brain barrier hinder progress. A comprehensive, multiscale understanding of the disease, from the molecular to the whole tumor level, is needed to address the intratumor heterogeneity resulting from the coexistence of a diversity of neoplastic and non-neoplastic cell types in the tumor tissue. By contrast, inter-patient variability must be addressed by subtyping brain tumors to stratify patients and identify the best-matched drug(s) and therapies for a particular patient or cohort of patients. Accomplishing these diverse tasks will require a new framework, one involving a systems perspective in assessing the immense complexity of brain tumors. This would in turn entail a shift in how clinical medicine interfaces with the rapidly advancing high-throughput (HTP) technologies that have enabled the omics-scale profiling of molecular features of brain tumors from the single-cell to the tissue level. However, several gaps must be closed before such a framework can fulfill the promise of precision and personalized medicine for brain tumors. Ultimately, the goal is to integrate seamlessly multiscale systems analyses of patient tumors and clinical medicine. Accomplishing this goal would facilitate the rational design of therapeutic strategies matched to the characteristics of patients and their tumors. Here, we discuss some of the technologies, methodologies, and computational tools that will facilitate the realization of this vision to practice.

oncology
Personalized Radiotherapy Design for Glioblastoma: Integrating Mathematical Tumor Models, Multimodal Scans and Bayesian Inference

Jana Lipkova,Panagiotis Angelikopoulos,Stephen Wu,Esther Alberts,Benedikt Wiestler,Christian Diehl,Christine Preibisch,Thomas Pyka,Stephanie Combs,Panagiotis Hadjidoukas,Koen Van Leemput,Petros Koumoutsakos,John S. Lowengrub,Bjoern Menze

DOI: https://doi.org/10.1109/TMI.2019.2902044

2019-03-12

Abstract:Glioblastoma is a highly invasive brain tumor, whose cells infiltrate surrounding normal brain tissue beyond the lesion outlines visible in the current medical scans. These infiltrative cells are treated mainly by radiotherapy. Existing radiotherapy plans for brain tumors derive from population studies and scarcely account for patient-specific conditions. Here we provide a Bayesian machine learning framework for the rational design of improved, personalized radiotherapy plans using mathematical modeling and patient multimodal medical scans. Our method, for the first time, integrates complementary information from high resolution MRI scans and highly specific FET-PET metabolic maps to infer tumor cell density in glioblastoma patients. The Bayesian framework quantifies imaging and modeling uncertainties and predicts patient-specific tumor cell density with confidence intervals. The proposed methodology relies only on data acquired at a single time point and thus is applicable to standard clinical settings. An initial clinical population study shows that the radiotherapy plans generated from the inferred tumor cell infiltration maps spare more healthy tissue thereby reducing radiation toxicity while yielding comparable accuracy with standard radiotherapy protocols. Moreover, the inferred regions of high tumor cell densities coincide with the tumor radioresistant areas, providing guidance for personalized dose-escalation. The proposed integration of multimodal scans and mathematical modeling provides a robust, non-invasive tool to assist personalized radiotherapy design.

Computational Engineering, Finance, and Science
Targeted therapies: how personal should we go?

Miriam Martini,Loredana Vecchione,Salvatore Siena,Sabine Tejpar,Alberto Bardelli

DOI: https://doi.org/10.1038/nrclinonc.2011.164

IF: 78.8

2011-11-15

Nature Reviews Clinical Oncology

Abstract:This Review discusses recent evidence that indicates that different genetic alterations might be related to distinct sensitivity to targeted therapies. It examines prototypical examples and asks what is the role of cancer mutations as predictors of sensitivity and resistance to targeted therapies? Further, what are the implications for the 'personalized' treatment of cancer patients?

oncology
Organoid-based personalized medicine: from tumor outcome prediction to autologous transplantation

Abel Soto-Gamez,Jennifer P Gunawan,Lara Barazzuol,Sarah Pringle,Robert P Coppes

DOI: https://doi.org/10.1093/stmcls/sxae023

IF: 5.845

2024-03-26

Stem Cells

Abstract:Inter-individual variation largely influences disease susceptibility, as well as response to therapy. In a clinical context, the optimal treatment of a disease should consider inter-individual variation and formulate tailored decisions at an individual level. In recent years, emerging organoid technologies promise to capture part of an individual's phenotypic variability and prove helpful in providing clinically relevant molecular insights. Organoids are stem cell-derived three-dimensional models that contain multiple cell types that can self-organize and give rise to complex structures mimicking the organization and functionality of the tissue of origin. Organoids represent thus a more faithful recapitulation of the dynamics of the tissues of interest, compared to conventional monolayer cultures, thus supporting their use in evaluating disease prognosis, or as a tool to predict treatment outcomes. Additionally, the individualized nature of patient-derived organoids enables the use of autologous organoids as a source of transplantable material not limited by histocompatibility. An increasing amount of preclinical evidence has paved the way for clinical trials exploring the applications of organoid-based technologies, some of which are in phase I/II. This review focuses on the recent progress concerning the use of patient-derived organoids in personalized medicine, including (1) diagnostics and disease prognosis, (2) treatment outcome prediction to guide therapeutic advice and (3) organoid transplantation or cell-based therapies. We discuss examples of these potential applications and the challenges associated with their future implementation.

oncology,cell biology,hematology,biotechnology & applied microbiology,cell & tissue engineering
A Review of Personalized Therapeutic Strategies

Mar Ros-Buxó,Ezequiel Mauro,Tamara Sauri,Gemma Iserte,Carla Fuster-Anglada,Alba Díaz,Laura Sererols-Viñas,Silvia Affo,Alejandro Forner

DOI: https://doi.org/10.3390/curroncol31070266

2024-06-22

Current Oncology

Abstract:Biliary tract cancers (BTCs) are rare and aggressive malignancies with an increasing incidence and poor prognosis. The standard systemic treatment for BTCs has evolved to include immune checkpoint inhibitors associated with gemcitabine–cisplatin as first-line therapies. However, survival rates remain low, highlighting the critical need for personalized treatment strategies based on molecular profiling. Currently, significant advancements have been made in the molecular characterization of BTCs, where genetic alterations, such as IDH1 mutations and FGFR2 fusions, provide targets for therapy. Molecular profiling is crucial early in the management process to identify potential candidates for clinical trials and guide treatment strategy. The integration of these molecular insights into clinical practice has allowed for the development of targeted therapies, although many of them are still in the phase 2 trial stage without definitive survival benefits demonstrated in phase 3 trials. This integration of comprehensive molecular profile insights with traditional treatment approaches offers a new horizon in the personalized medicine landscape for BTCs, with the aim of significantly improving patient outcomes through precision oncology.

oncology
Editorial: Molecular characteristics and personalized treatment for pediatric brain tumors

Weijun Feng,Daisuke Kawauchi,Feng Wan

DOI: https://doi.org/10.3389/fonc.2022.1114280

IF: 4.7

2022-01-01

Frontiers in Oncology

Abstract:EDITORIAL article Front. Oncol., 29 December 2022Sec. Neuro-Oncology and Neurosurgical Oncology Volume 12 - 2022 | https://doi.org/10.3389/fonc.2022.1114280
Preliminary experience with personalized and targeted therapy for pediatric brain tumors

Johannes E Wolff,Robert E Brown,Jamie Buryanek,Stefan Pfister,Tribhawan S Vats,Michael E Rytting

DOI: https://doi.org/10.1002/pbc.23402

2012-07-15

Abstract:Background: A new generation of anticancer drugs has reached clinical care in common diseases, but their use in rare diseases such as pediatric brain tumors lags behind since conventional clinical trial design requires larger patient numbers. Procedure: We designed individualized treatment protocols for pediatric patients with relapsed brain tumors, based upon the patient's treatment history. In addition, each tumor was analyzed with morphoproteomics using a panel of markers to show treatment targets, resulting in a list of potential novel drugs to be added to chemotherapy. Here, we present the concept and report the experiences of the first patients enrolled in the program. Results: Eleven treatment protocols were designed using morphoproteomic information and given to eight patients. The histological diagnoses included: medulloblastoma (n = 3), glioblastoma multiforme (n = 2), atypical teratoid rhabdoid tumor (n = 1), choroid plexus carcinoma (n = 1), and primitive neuroectodermal tumors (n = 1). Tumor markers included p-ERK, Topoisomerase IIa, Bcl-2, VEGF-A, p-STAT3, ER-beta, p-mTOR, and p-NF-kappaBp65. The novel agents included sorafenib, bevacizumab, fulvestrant, rapamycin, bortezomib, and curcumin. The response to the first protocol was complete response: 1, partial response: 1, stable disease: 0, progressive disease: 4, and continuous complete remission: 2. The median Event-Free Survival was 0.32 year ± 0.4. For the comparison with the institutional control group, the individual response probability was calculated. The observed response was superior to the historical controls (P = 0.006 Whitman U-test). Conclusion: This approach warrants further, systematic evaluation as proof of concept and then expansion to drug-specific hypotheses.
Innovating Strategies and Tailored Approaches in Neuro-Oncology

Alberto Picca,David Guyon,Orazio Santo Santonocito,Capucine Baldini,Ahmed Idbaih,Alexandre Carpentier,Antonio Giuseppe Naccarato,Mario Caccese,Giuseppe Lombardi,Anna Luisa Di Stefano

DOI: https://doi.org/10.3390/cancers14051124

2022-02-22

Abstract:Diffuse gliomas, the most frequent and aggressive primary central nervous system neoplasms, currently lack effective curative treatments, particularly for cases lacking the favorable prognostic marker IDH mutation. Nonetheless, advances in molecular biology allowed to identify several druggable alterations in a subset of IDH wild-type gliomas, such as NTRK and FGFR-TACC fusions, and BRAF hotspot mutations. Multi-tyrosine kinase inhibitors, such as regorafenib, also showed efficacy in the setting of recurrent glioblastoma. IDH inhibitors are currently in the advanced phase of clinical evaluation for patients with IDH-mutant gliomas. Several immunotherapeutic approaches, such as tumor vaccines or checkpoint inhibitors, failed to improve patients' outcomes. Even so, they may be still beneficial in a subset of them. New methods, such as using pulsed ultrasound to disrupt the blood-brain barrier, gene therapy, and oncolytic virotherapy, are well tolerated and may be included in the therapeutic armamentarium soon.
Precision based approach to tailoring radiotherapy in the multidisciplinary management of pediatric central nervous system tumors

Christina Phuong,Bo Qiu,Sabine Mueller,Steve E Braunstein

DOI: https://doi.org/10.1016/j.jncc.2023.03.001

2023-04-06

Abstract:Modern day survivorship from childhood malignancies is estimated to be over 80%. However, central nervous system tumors remain the leading cause of cancer mortality in children and is the most common solid tumor in this population. Improved survivorship is, in part, a result of improved multidisciplinary care, often with a combination of surgery, radiation therapy, and systemic therapy. With improved survival, long term effects of treatment and quality of life impacts have been recognized and pose a challenge to maximize the therapeutic ratio of treatment. It has been increasingly more apparent that precise risk stratification, such as with the inclusion of molecular classification, is instrumental in efforts to tailor radiotherapy for appropriate treatment, generally towards de-intensification for this vulnerable patient population. In addition, advances in radiotherapy techniques have allowed greater conformality and accuracy of treatment for those who do require radiotherapy for tumor control. Ongoing efforts to tailor radiotherapy, including de-escalation, omission, or intensification of radiotherapy, continue to improve as increasing insight into tumor heterogeneity is recognized, coupled with advances in precision medicine employing novel molecularly-targeted therapeutics.

Personalized Medicine in Brain Tumors

Personalization of medical treatments in oncology: time for rethinking the disease concept to improve individual outcomes

Personalized Medicine for Patients with Liver, Biliary Tract, and Pancreatic Cancer

Personalized medicine: Clinical oncology on molecular view of treatment

Personalized Medicine: Recent Progress in Cancer Therapy

Foundations for a Personalized Psycho-Oncology: The State of the Art

Personalized Clinical Phenotyping through Systems Medicine and Artificial Intelligence

Personalized Cancer Therapy Using a Patient-Derived Tumor Tissue Xenograft Model: a Translational Field Worthy of Exploring Further?

Advances in Personalized Oncology

Nanomedicine for cancer patient-centered care

Personalised Medicine: Taking a New Look at the Patient

Hacking Pancreatic Cancer: Present and Future of Personalized Medicine

A Systems Approach to Brain Tumor Treatment

Personalized Radiotherapy Design for Glioblastoma: Integrating Mathematical Tumor Models, Multimodal Scans and Bayesian Inference

Targeted therapies: how personal should we go?

Organoid-based personalized medicine: from tumor outcome prediction to autologous transplantation

A Review of Personalized Therapeutic Strategies

Editorial: Molecular characteristics and personalized treatment for pediatric brain tumors

Preliminary experience with personalized and targeted therapy for pediatric brain tumors

Innovating Strategies and Tailored Approaches in Neuro-Oncology

Precision based approach to tailoring radiotherapy in the multidisciplinary management of pediatric central nervous system tumors